Coherus BioSciences

Historical price data

Coherus BioSciences has successfully pivoted from a pure-play biosimilar company to an integrated oncology firm with a dual revenue and R&D strategy. Its commercial biosimilars (UDENYCA®, YUSIMRY™) provide a cash-generative foundation, while its innovative immuno-oncology pipeline, anchored by the approved anti-PD-1 therapy LOQTORZI® (toripalimab) and novel candidates like tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27), targets significant market opportunities in oncology. The company's strategy is to leverage its commercial infrastructure and regulatory expertise to efficiently advance combination therapies that overcome immune resistance.

Integrated development, manufacturing, and commercialization platform for complex biologics, applied to both biosimilars and novel immuno-oncology antibody therapeutics targeting the tumor microenvironment.